BeiGene Total Change in Assets/Liabilities 2014-2024 | ONC
BeiGene annual/quarterly total change in assets/liabilities history and growth rate from 2014 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
- BeiGene total change in assets/liabilities for the quarter ending September 30, 2024 was $-0.138B, a 64.31% decline year-over-year.
- BeiGene total change in assets/liabilities for the twelve months ending September 30, 2024 was $-0.933B, a 6.19% increase year-over-year.
- BeiGene annual total change in assets/liabilities for 2023 was $-0.371B, a 379.88% decline from 2022.
- BeiGene annual total change in assets/liabilities for 2022 was $0.132B, a 211.87% decline from 2021.
- BeiGene annual total change in assets/liabilities for 2021 was $-0.118B, a 178.59% decline from 2020.
BeiGene Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2023 |
$-371 |
| 2022 |
$132 |
| 2021 |
$-118 |
| 2020 |
$151 |
| 2019 |
$-11 |
| 2018 |
$-17 |
| 2017 |
$57 |
| 2016 |
$15 |
| 2015 |
$2 |
| 2014 |
$-2 |
| 2013 |
$8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
